Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01676818 · ClinicalTrials.gov registry record · Phase 2
Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01676818 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 32 participants.
The verdict
NCT01676818, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This phase II trial studies how well eribulin mesylate works in treating patients with advanced or recurrent cervical cancer. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing
Interventions
- DRUG eribulin mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-08-09 |
| Est. Completion | 2021-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01676818
The ClinicalTrials.gov registry entry for NCT01676818 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eribulin mesylate is the first listed.
NCT01676818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01676818 about?
NCT01676818 is a clinical study titled "Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer". This phase II trial studies how well eribulin mesylate works in treating patients with advanced or recurrent cervical cancer. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing
What is the current status of trial NCT01676818?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2012-08-09. Estimated completion is 2021-12-22.
What interventions are being tested in trial NCT01676818?
The interventions under investigation include: eribulin mesylate (DRUG).
Who is sponsoring clinical trial NCT01676818?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.